(AOF) – Inventiva, a biopharmaceutical company specialized in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (“NASH”), announces today that it has received the payment of an amount of 25 million euros under the first tranche of the loan granted by the European Investment Bank (EIB) on May 16, 2022, which will mature in December 2026.
Inventiva announces that it will use the proceeds from this draw to finance part of the pivotal Phase III clinical study evaluating lanifibranor in patients with NASH. The company adds that this 25 million euros will support its cash consumption until the fourth quarter of 2023.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.